FORT MYERS, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- American Oncology Network, Inc. (“AON” or the “Company”) (Nasdaq: AONC), a rapidly growing network of community-based oncology practices, announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 14, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on the same day.
To access the call through a conference line, dial 1-877-704-4453 or for international callers, 1-201-389-0920. The passcode for the live call is 13741860. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The Access ID for the replay call is 13741860. The replay will be available until November 21, 2023.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at www.investors.aoncology.com.
About American Oncology Network
American Oncology Network (AON) (Nasdaq: AONC) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology and other specialties. Launched in 2018, the rapidly expanding AON network represents more than 220 providers practicing across 20 states. The executive management team of AON encompasses more than four decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.
The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.
AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at aoncology.com.
Investor Contact:
David Gould, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.00 |
Daily Change: | 2.01 50.38 |
Daily Volume: | 2,100 |
Market Cap: | US$162.480M |
October 29, 2024 July 11, 2024 June 04, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load